Regulus Therapeutics Inc. (RGLS)
1.95
0.20 (11.43%)
At close: Apr 02, 2025, 3:59 PM
1.85
-4.72%
After-hours: Apr 02, 2025, 07:54 PM EDT
Regulus Therapeutics Income Statement
Financials in USD. Fiscal year
is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
| Revenue | n/a | n/a | n/a | n/a | 10.01M | 6.83M | 72K | 72K | 1.19M | 20.76M | 7.67M | 19.57M | 12.7M | 13.79M | 8.6M |
| Cost of Revenue | n/a | 21.15M | 122K | 459K | 15.35K | 12.35K | 33.98M | 54.59M | 64.31M | 56.39M | 41.05M | 29.94M | 20.34K | n/a | n/a |
| Gross Profit | n/a | -21.15M | -122K | -459K | 9.99M | 6.82M | -33.9M | -54.52M | -63.11M | -35.63M | -33.38M | -10.37M | 12.68M | 13.79M | 8.6M |
| Operating Income | -50.04M | -31.11M | -28.24M | -27.82M | -14.15M | -16.83M | -46.76M | -70.13M | -81.5M | -54.76M | -44.91M | -17.8M | -12.57M | -7.14M | -15.5M |
| Interest Income | 3.84M | 1.68M | 605K | 864K | 233K | 374K | 459K | 752K | 844K | 855K | 388K | 292K | 110K | 128K | 271K |
| Pretax Income | -46.36M | -30.04M | -28.32M | -27.81M | -15.73M | -18.59M | -48.65M | -72.1M | -81.84M | -55.77M | -56.68M | -18.69M | -17.42M | -7.4M | -15.59M |
| Net Income | -46.36M | -30.04M | -28.32M | -27.81M | -15.26M | -18.59M | -48.71M | -71.91M | -81.84M | -55.75M | -56.68M | -18.67M | -17.41M | -7.6M | -15.56M |
| Selling & General & Admin | 14.67M | 9.96M | 9.83M | 10.02M | 8.81M | 11.32M | 12.86M | 17.01M | 18.39M | 19.13M | 11.53M | 7.43M | 4.93M | 3.64M | 3.92M |
| Research & Development | 35.37M | 21.01M | 18.41M | 17.79M | 15.35M | 12.35M | 33.98M | 53.19M | 64.31M | 56.39M | 41.05M | 29.94M | 20.34M | 17.29M | 20.18M |
| Other Expenses | n/a | -21.01M | -83K | 9K | -1.57M | -1.76M | -1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 3.64M | 3.92M |
| Operating Expenses | 50.04M | 9.96M | 28.24M | 27.82M | 24.16M | 23.67M | 46.84M | 70.2M | 82.7M | 75.52M | 52.58M | 37.37M | 25.27M | 20.93M | 24.1M |
| Interest Expense | 158K | 604K | 688K | 855K | 1.81M | 2.13M | 2.34M | 2.72M | 1.18M | 52K | 39K | 36K | 247K | 388K | 362K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 50.04M | 31.11M | 28.24M | 27.82M | 24.16M | 23.67M | 46.84M | 70.2M | 82.7M | 75.52M | 52.58M | 37.37M | 25.27M | 20.93M | 24.1M |
| Income Tax | 1K | 1K | 1K | 1K | -467K | 1K | 62K | -197K | -4K | -18K | 1K | -23K | -10K | 206K | -30K |
| Shares Outstanding (Basic) | 56.35M | 18.96M | 15.26M | 8.57M | 3.5M | 1.73M | 871.86K | 626.92K | 440.11K | 428.43K | 367.42K | 320.66K | 68.44K | 2.14K | 2.14K |
| Shares Outstanding (Diluted) | 56.35M | 18.96M | 15.26M | 8.57M | 3.5M | 1.73M | 871.86K | 626.92K | 440.11K | 428.43K | 367.42K | 320.66K | 68.44K | 2.14K | 2.14K |
| EPS (Basic) | -0.82 | -1.58 | -1.86 | -3.24 | -4.36 | -10.77 | -55.87 | -114.7 | -185.94 | -130.12 | -154.27 | -58.22 | -254.37 | -3.55K | -7.27K |
| EPS (Diluted) | -0.82 | -1.58 | -1.86 | -3.24 | -4.36 | -10.77 | -55.87 | -114.7 | -185.94 | -130.12 | -154.27 | -58.22 | -254.37 | -3.55K | -7.27K |
| EBITDA | -45.85M | -30.88M | -28.12M | -27.36M | -13.46M | -15.53M | -44.04M | -66.86M | -78.38M | -54.12M | -55.15M | -17.3M | -16.15M | -6.1M | -14.73M |
| EBIT | -46.2M | -31.11M | -28.24M | -27.82M | -13.92M | -16.46M | -46.3M | -69.38M | -80.66M | -55.71M | -56.64M | -18.66M | -17.17M | -7.01M | -15.23M |
| Depreciation & Amortization | 347K | 227K | 122K | 459K | 467K | 931K | 2.26M | 2.52M | 2.28M | 1.59M | 1.49M | 1.36M | 1.02M | 911K | 494K |